Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion

B. A. Harms, D. J. Rosenfeld, R. L. Conhaim, A. C. Pahl, R. Subramanian, F. K. Storm

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Interleukin-2 has been widely investigated as adjuvant therapy for advanced cancer and is administered by either bolus or continuous infusion. We compared the effects of bolus and continuous interleukin-2 infusion on pulmonary (Q(L)) and systemic microvascular fluid filtration in 11 adult sheep prepared with chronic lung and soft-tissue lymph fistulas. Interleukin-2 was administered as a bolus infusion (100,000 units/kg) every 8 hours for 3 days or as a continuous infusion at the same dose for 3 days. No significant changes in pulmonary hydrostatic pressures or pulmonary vascular resistance were noted after either bolus or continuous interleukin-2 infusion. However, significantly decreased (p ≤ 0.05) systemic vascular resistances were observed in both groups. Q(L) increased steadily throughout the infusion period in both groups, peaking at three times baseline on the third infusion day. The plasma/interstitial protein clearance (Q(L) x lymph/plasma protein ratio) rose similarly in both groups, indicating increased barrier permeability. Increased lymphocyte clearance into lung lymph occurred by day 3 but was not associated with lymphocytic sequestration in the lung interstitium. We conclude that pulmonary and systemic microvascular fluid and protein flux exhibit similar changes after bolus or continuous interleukin-2 infusion. These changes are associated with increased clearance of lymphocytes into lung lymph that are not sequestered in the pulmonary interstitium after infusions of shorter duration.

Original languageEnglish (US)
Pages (from-to)500-507
Number of pages8
JournalSurgery
Volume110
Issue number3
StatePublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Pulmonary and systemic fluid filtration after continuous versus bolus interleukin-2 infusion'. Together they form a unique fingerprint.

Cite this